CoChat
Sign Up
Cited by 568

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets

Jun, Joon-Il, Lau, Lester F.·2011·Nature Reviews Drug Discovery
DOI 10.1038/nrd3599PMC PMC3663145
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd3599

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 191

  1. Bornstein, P. & Sage, E. H. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14, 608–616 (2002). · DOI
  2. Chen, C.-C. & Lau, L. F. Functions and mechanisms of action of CCN matricellular proteins. Int. J. Biochem. Cell Biol. 41, 771–783 (2009). · DOI · Paper page
  3. Leask, A. & Abraham, D. J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J. Cell Sci. 119, 4803–4810 (2006). · DOI
  4. Holbourn, K. P., Acharya, K. R. & Perbal, B. The CCN family of proteins: structure-function relationships. Trends Biochem. Sci. 33, 461–473 (2008). · DOI
  5. Perbal, B. & Takigawa, M. (eds) CCN Proteins: A New Family of Cell Growth and Differentiation Regulators (Imperial College Press, London, 2005). This monograph is a collection of reviews on various aspects of CCN biology. · DOI
  6. Adler, S. G. et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin. J. Am. Soc. Nephrol. 5, 1420–1428 (2010). This paper reports that in a Phase I clinical trial, treatment with the humanized monoclonal CCN2-specific antibody FG-3019 is well tolerated in patients with microalbuminuric diabetic kidney disease, and the treatment is associated with a decrease in albuminuria. · DOI
  7. Todorovic, V., Chen, C.-C., Hay, N. & Lau, L. F. The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts. J. Cell Biol. 171, 559–568 (2005). · DOI · Paper page
  8. Lillis, A. P., Van Duyn, L. B., Murphy-Ullrich, J. E. & Strickland, D. K. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 88, 887–918 (2008). · DOI · Paper page
  9. Mercurio, S., Latinkic, B., Itasaki, N., Krumlauf, R. & Smith, J. C. Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex. Development 131, 2137–2147 (2004). · DOI
  10. Wahab, N. A., Weston, B. S. & Mason, R. M. Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J. Am. Soc. Nephrol. 16, 340–351 (2005). · DOI
  11. Edwards, L. A. et al. Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J. Natl Cancer Inst. 103, 1162–1178 (2011). · DOI
  12. Sakamoto, K. et al. The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway. J. Biol. Chem. 277, 29399–29405 (2002). · DOI
  13. Minamizato, T. et al. CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways. Biochem. Biophys. Res. Commun. 354, 567–573 (2007). · DOI
  14. Nakanishi, T. et al. Effects of CTGF/Hcs24, a product of a hypertrophic chondrocyte-specific gene, on the proliferation and differentiation of chondrocytes in culture. Endocrinology 141, 264–273 (2000). · DOI
  15. Safadi, F. F. et al. Expression of connective tissue growth factor in bone: its role in osteoblast proliferation and differentiation in vitro and bone formation in vivo. J. Cell Physiol. 196, 51–62 (2003). · DOI
  16. Abdel-Wahab, N., Weston, B. S., Roberts, T. & Mason, R. M. Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J. Am. Soc. Nephrol. 13, 2437–2445 (2002). · DOI
  17. Benini, S. et al. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 24, 4349–4361 (2005). · DOI
  18. Fan, W. H., Pech, M. & Karnovsky, M. J. Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro. Eur. J. Cell Biol. 79, 915–923 (2000). · DOI
  19. Lake, A. C., Bialik, A., Walsh, K. & Castellot, J. J. Jr. CCN5 is a growth arrest-specific gene that regulates smooth muscle cell proliferation and motility. Am. J. Pathol. 162, 219–231 (2003). · DOI
  20. Shimoyama, T. et al. CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migration. Arterioscler. Thromb. Vasc. Biol. 30, 675–682 (2010). · DOI
  21. Juric, V., Chen, C. C. & Lau, L. F. Fas-mediated apoptosis is regulated by the extracellular matrix protein CCN1 (CYR61) in vitro and in vivo. Mol. Cell. Biol. 29, 3266–3279 (2009). · DOI · Paper page
  22. Franzen, C. A. et al. The matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis. Mol. Cancer Res. 7, 1045–1055 (2009). · DOI · Paper page
  23. Venkatachalam, K. et al. WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-α (TNF-α)-stimulated cardiac fibroblast proliferation but inhibits TNF-α-induced cardiomyocyte death. J. Biol. Chem. 284, 14414–14427 (2009). · DOI
  24. Babic, A. M., Kireeva, M. L., Kolesnikova, T. V. & Lau, L. F. CYR61, product of a growth factor-inducible immediate-early gene, promotes angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA 95, 6355–6360 (1998). This paper was the first to report the discovery of angiogenic activity in a CCN protein; this research showed that this angiogenic function is mediated through αVβ3 integrin, and that CCN1 promotes tumour growth by enhancing vascular density. · DOI · Paper page
  25. Kubota, S. & Takigawa, M. CCN family proteins and angiogenesis: from embryo to adulthood. Angiogenesis 10, 1–11 (2007). · DOI
  26. Mo, F. E. et al. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol. Cell Biol. 22, 8709–8720 (2002). This paper describes the Ccn1 -knockout phenotypes in mice and establishes CCN1 functions in placentation and cardiovascular development. · DOI · Paper page
  27. Inoki, I. et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 16, 219–221 (2002). · DOI
  28. Dean, R. A. et al. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol. Cell Biol. 27, 8454–8465 (2007). · DOI
  29. Kular, L., Pakradouni, J., Kitabgi, P., Laurent, M. & Martinerie, C. The CCN family: a new class of inflammation modulators? Biochimie 93, 377–388 (2010). This is a thorough review of CCN protein expression and function in inflammation and inflammation-related pathologies. · DOI · Paper page
  30. Kubota, S. & Takigawa, M. The role of CCN2 in cartilage and bone development. J. Cell Commun. Signal. 5, 209–217 (2011). · DOI
  31. Abreu, J. G., Ketpura, N. I., Reversade, B. & De Robertis, E. M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β. Nature Cell Biol. 4, 599–604 (2002). This paper was the first to show that CCN proteins can bind to TGFβ and BMPs to modulate the activities of these proteins. · DOI
  32. Maeda, A. et al. CCN family 2/connective tissue growth factor modulates BMP signalling as a signal conductor, which action regulates the proliferation and differentiation of chondrocytes. J. Biochem. 145, 207–216 (2009). · DOI
  33. Ono, M., Inkson, C. A., Kilts, T. M. & Young, M. F. WISP-1/CCN4 regulates osteogenesis by enhancing BMP-2 activity. J. Bone Miner. Res. 26, 193–208 (2011). · DOI
  34. Ouellet, V. et al. CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. Am. J. Pathol. 178, 2377–2388 (2011). · DOI
  35. Rydziel, S. et al. Nephroblastoma overexpressed (Nov) inhibits osteoblastogenesis and causes osteopenia. J. Biol. Chem. 282, 19762–19772 (2007). · DOI
  36. Smerdel-Ramoya, A., Zanotti, S., Stadmeyer, L., Durant, D. & Canalis, E. Skeletal overexpression of connective tissue growth factor impairs bone formation and causes osteopenia. Endocrinology 149, 4374–4381 (2008). · DOI
  37. Rother, M. et al. Matricellular signaling molecule CCN1 attenuates experimental autoimmune myocarditis by acting as a novel immune cell migration modulator. Circulation 122, 2688–2698 (2010). · DOI
  38. Lin, Z. et al. A novel role of CCN3 in regulating endothelial inflammation. J. Cell Commun. Signal. 4, 141–153 (2010). · DOI
  39. Lee, C. H., Shah, B., Moioli, E. K. & Mao, J. J. CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. J. Clin. Invest. 120, 3340–3349 (2010). · DOI
  40. Luo, Q. et al. Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J. Biol. Chem. 279, 55958–55968 (2004). · DOI
  41. Si, W. et al. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol. Cell Biol. 26, 2955–2964 (2006). · DOI · Paper page
  42. Gupta, R., Hong, D., Iborra, F., Sarno, S. & Enver, T. NOV (CCN3) functions as a regulator of human hematopoietic stem or progenitor cells. Science 316, 590–593 (2007). This paper was the first to show that CCN3 is crucial for self-renewal of haematopoietic stem cells, confers a selective engraftment potential and is important for the development of the myelomonocytic and erythroid lineages. · DOI
  43. Katsuki, Y. et al. Inhibitory effect of CT domain of CCN3/NOV on proliferation and differentiation of osteogenic mesenchymal stem cells, Kusa-A1. Biochem. Biophys. Res. Commun. 368, 808–814 (2008). · DOI
  44. Sheffield, V. C. et al. Identification of a complex congenital heart defect susceptibility locus by using DNA pooling and shared segment analysis. Hum. Mol. Genet. 6, 117–121 (1997). · DOI · Paper page
  45. Ivkovic, S. et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 130, 2779–2791 (2003). This paper describes the Ccn2 -knockout phenotypes in mice and establishes the crucial functions of CCN2 in skeletal development. · DOI
  46. Baguma-Nibasheka, M. & Kablar, B. Pulmonary hypoplasia in the connective tissue growth factor (Ctgf) null mouse. Dev. Dyn. 237, 485–493 (2008). · DOI
  47. Crawford, L. A. et al. Connective tissue growth factor (CTGF) inactivation leads to defects in islet cell lineage allocation and β-cell proliferation during embryogenesis. Mol. Endocrinol. 23, 324–336 (2009). · DOI
  48. Nagashima, T. et al. Connective tissue growth factor is required for normal follicle development and ovulation. Mol. Endocrinol. 25, 1740–1759 (2011). · DOI
  49. Canalis, E. et al. Nephroblastoma overexpressed (Nov) inactivation sensitizes osteoblasts to bone morphogenetic protein-2, but Nov is dispensable for skeletal homeostasis. Endocrinology 151, 221–233 (2010). · DOI
  50. Russo, J. W. & Castellot, J. J. CCN5: biology and pathophysiology. J. Cell Commun. Signal. 4, 119–130 (2010). · DOI
  51. Kutz, W. E., Gong, Y. & Warman, M. L. WISP3, the gene responsible for the human skeletal disease progressive pseudorheumatoid dysplasia, is not essential for skeletal function in mice. Mol. Cell Biol. 25, 414–421 (2005). · DOI
  52. Cicha, I., Garlichs, C. D., Daniel, W. G. & Goppelt-Struebe, M. Activated human platelets release connective tissue growth factor. Thromb. Haemost. 91, 755–760 (2004). · DOI
  53. Kubota, S. et al. Abundant retention and release of connective tissue growth factor (CTGF/CCN2) by platelets. J. Biochem. 136, 279–282 (2004). · DOI
  54. Brigstock, D. R. Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J. Cell Commun. Signal. 4, 1–4 (2009). · DOI
  55. Mori, T. et al. Role and interaction of connective tissue growth factor with transforming growth factor-β in persistent fibrosis: a mouse fibrosis model. J. Cell Physiol. 181, 153–159 (1999). This paper establishes that CCN2 and TGFβ act synergistically to promote fibrosis in vivo. · DOI
  56. Leask, A., Parapuram, S. K., Shi-wen, X. & Abraham, D. J. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J. Cell Commun. Signal. 3, 89–94 (2009). · DOI
  57. Phanish, M. K., Winn, S. K. & Dockrell, M. E. Connective tissue growth factor-(CTGF, CCN2) — a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp. Nephrol. 114, e83–e92 (2010). · DOI
  58. Sonnylal, S. et al. Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum. 62, 1523–1532 (2010). This study shows that selective expression of CCN2 in fibroblasts alone can promote tissue fibrosis in vivo , suggesting that the action of CCN2 is strongly autocrine in nature. · DOI
  59. Liu, S., Shi-wen, X., Abraham, D. J. & Leask, A. CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum. 63, 239–246 (2011). · DOI
  60. Uchio, K., Graham, M., Dean, N. M., Rosenbaum, J. & Desmouliere, A. Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis. Wound Repair Regen. 12, 60–66 (2004). · DOI
  61. Li, G. et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J. Gene Med. 8, 889–900 (2006). · DOI
  62. George, J. & Tsutsumi, M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther. 14, 790–803 (2007). · DOI
  63. Yokoi, H. et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 15, 1430–1440 (2004). · DOI
  64. Sisco, M. et al. Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo. Wound Repair Regen. 16, 661–673 (2008). · DOI
  65. Okada, H. et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J. Am. Soc. Nephrol. 16, 133–143 (2005). · DOI
  66. Riser, B. L. et al. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am. J. Pathol. 174, 1725–1734 (2009). · DOI
  67. Yoon, P. O. et al. The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis. J. Mol. Cell Cardiol. 49, 294–303 (2010). · DOI
  68. Schafer, M. & Werner, S. Cancer as an overhealing wound: an old hypothesis revisited. Nature Rev. Mol. Cell Biol. 9, 628–638 (2008). · DOI
  69. Dhar, A. & Ray, A. The CCN family proteins in carcinogenesis. Exp. Oncol. 32, 2–9 (2010).
  70. Dobroff, A. S. et al. Silencing cAMP-response element binding protein (CREB) identifies cysteine-rich protein 61 (CYR61) as a tumor suppressor gene in melanoma. J. Biol. Chem. 284, 26194–26206 (2009). · DOI · Paper page
  71. Lin, B. R. et al. Connective tissue growth factor acts as a therapeutic agent and predictor for peritoneal carcinomatosis of colorectal cancer. Clin. Cancer Res. 17, 3077–3088 (2011). · DOI
  72. Shimo, T. et al. Involvement of CTGF, a hypertrophic chondrocyte-specific gene product, in tumor angiogenesis. Oncology 61, 315–322 (2001). · DOI
  73. Xie, D. et al. Breast cancer: Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J. Biol. Chem. 276, 14187–14194 (2001). · DOI · Paper page
  74. Yang, F. et al. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 65, 8887–8895 (2005). · DOI
  75. Yin, D. et al. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int. J. Cancer 127, 2257–2267 (2010). · DOI
  76. Bennewith, K. L. et al. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 69, 775–784 (2009). · DOI
  77. Haque, I. et al. Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol. Cancer 10, 8 (2011). · DOI · Paper page
  78. Gery, S. et al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin. Cancer Res. 11, 7243–7254 (2005). · DOI · Paper page
  79. Shi, Y. et al. Homologous peptide of connective tissue growth factor ameliorates epithelial to mesenchymal transition of tubular epithelial cells. Cytokine 36, 35–44 (2006). · DOI
  80. Wang, M. Y. et al. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res. 69, 3482–3491 (2009). · DOI
  81. Lai, D., Ho, K. C., Hao, Y. & Yang, X. Taxol resistance in breast cancer cells is mediated by the Hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 71, 2728–2738 (2011). · DOI · Paper page
  82. Goodwin, C. R. et al. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. Cancer Res. 70, 2932–2941 (2010). · DOI · Paper page
  83. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537–549 (2003). · DOI
  84. Shimo, T. et al. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J. Bone Miner. Res. 21, 1045–1059 (2006). · DOI
  85. Dornhofer, N. et al. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 66, 5816–5827 (2006). This study shows that using a CCN2-specific monoclonal antibody (FG-3019) to treat mice with pre-established pancreatic tumours results in inhibition of tumour growth and metastasis without any toxicity observed in normal tissues. · DOI
  86. Aikawa, T., Gunn, J., Spong, S. M., Klaus, S. J. & Korc, M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol. Cancer Ther. 5, 1108–1116 (2006). This study shows that the treatment of orthotopically implanted pancreatic tumours in nude mice with the monoclonal antibody FG-3019 decreases tumour growth and metastasis. · DOI
  87. Xu, L., Corcoran, R. B., Welsh, J. W., Pennica, D. & Levine, A. J. WISP-1 is a Wnt-1- and β-catenin-responsive oncogene. Genes Dev. 14, 585–595 (2000). · DOI
  88. Xie, D., Nakachi, K., Wang, H., Elashoff, R. & Koeffler, H. P. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 61, 8917–8923 (2001).
  89. Tian, C. et al. Overexpression of connective tissue growth factor WISP-1 in Chinese primary rectal cancer patients. World J. Gastroenterol. 13, 3878–3882 (2007). · DOI
  90. Chen, P. P. et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS ONE 2, e534 (2007). · DOI · Paper page
  91. Hashimoto, Y. et al. Expression of the Elm1 gene, a novel gene of the CCN (connective tissue growth factor, Cyr61/Cef10, and neuroblastoma overexpressed gene) family, suppresses in vivo tumor growth and metastasis of K-1735 murine melanoma cells. J. Exp. Med. 187, 289–296 (1998). · DOI
  92. Soon, L. L. et al. Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J. Biol. Chem. 278, 11465–11470 (2003). · DOI
  93. Tanaka, S. et al. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene 20, 5525–5532 (2001). · DOI
  94. Bleau, A. M. et al. Antiproliferative activity of CCN3: involvement of the C-terminal module and post-translational regulation. J. Cell Biochem. 101, 1475–1491 (2007). · DOI
  95. Gupta, N. et al. Inhibition of glioma cell growth and tumorigenic potential by CCN3 (NOV). Mol. Pathol. 54, 293–299 (2001). · DOI
  96. Vallacchi, V. et al. CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res. 68, 715–723 (2008). · DOI
  97. Perbal, B. et al. Prognostic relevance of CCN3 in Ewing sarcoma. Hum. Pathol. 40, 1479–1486 (2009). · DOI
  98. Ghayad, S. E. et al. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J. Mol. Endocrinol. 42, 87–103 (2009). · DOI
  99. McCallum, L. et al. A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 108, 1716–1723 (2006). · DOI
  100. McCallum, L. et al. CCN3 suppresses mitogenic signalling and reinstates growth control mechanisms in chronic myeloid leukaemia. J. Cell Commun. Signal. 20 Jul 2011 (doi:10.1007/s12079-011-0142-2). · DOI
  101. Kleer, C. G. et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 21, 3172–3180 (2002). · DOI
  102. Lorenzatti, G., Huang, W., Pal, A., Cabanillas, A. M. & Kleer, C. G. CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer. J. Cell Sci. 124, 1752–1758 (2011). · DOI
  103. Navarro-Gonzalez, J. F., Mora-Fernandez, C., Muros de, F. M. & Garcia-Perez, J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nature Rev. Nephrol. 7, 327–340 (2011). · DOI
  104. Tang, J. & Kern, T. S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 30, 343–358 (2011). · DOI
  105. Yan, S. F., Ramasamy, R. & Schmidt, A. M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nature Clin. Pract. Endocrinol. Metab. 4, 285–293 (2008). · DOI
  106. Murphy, M. et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J. Biol. Chem. 274, 5830–5834 (1999). · DOI
  107. Twigg, S. M. et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143, 4907–4915 (2002). · DOI
  108. Hughes, J. M. et al. Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia 50, 1089–1098 (2007). · DOI
  109. Chaqour, B. & Goppelt-Struebe, M. Mechanical regulation of the Cyr61/CCN1 and CTGF/CCN2 proteins. FEBS J. 273, 3639–3649 (2006). · DOI
  110. Mason, R. M. Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J. Cell Commun. Signal. 3, 95–104 (2009). · DOI
  111. Sawai, K. et al. Expression of CCN1 (CYR61) in developing, normal, and diseased human kidney. Am. J. Physiol. Renal Physiol. 293, F1363–F1372 (2007). · DOI · Paper page
  112. Sanchez-Lopez, E. et al. CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-κB. J. Am. Soc. Nephrol. 20, 1513–1526 (2009). · DOI
  113. Guha, M., Xu, Z. G., Tung, D., Lanting, L. & Natarajan, R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 21, 3355–3368 (2007). · DOI
  114. Yokoi, H. et al. Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int. 73, 446–455 (2008). · DOI
  115. Wolf, G. & Ritz, E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 67, 799–812 (2005). · DOI
  116. Jaffa, A. A. et al. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J. Clin. Endocrinol. Metab. 93, 1893–1900 (2008). · DOI
  117. Nguyen, T. Q. et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 31, 1177–1182 (2008). · DOI
  118. You, J. J., Yang, C. H., Chen, M. S. & Yang, C. M. Cysteine-rich 61, a member of the CCN family, as a factor involved in the pathogenesis of proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 50, 3447–3455 (2009). · DOI
  119. Kuiper, E. J. et al. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch. Ophthalmol. 124, 1457–1462 (2006). · DOI · Paper page
  120. Kuiper, E. J. et al. Connective tissue growth factor is necessary for retinal capillary basal lamina thickening in diabetic mice. J. Histochem. Cytochem. 56, 785–792 (2008). · DOI
  121. Hilfiker, A. et al. Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II. Circulation 106, 254–260 (2002). · DOI · Paper page
  122. Cicha, I. et al. Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro. Arterioscler. Thromb. Vasc. Biol. 25, 1008–1013 (2005). · DOI
  123. Kundi, R. et al. Arterial gene transfer of the TGF-β signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. Cardiovasc. Res. 84, 326–335 (2009). · DOI
  124. Lee, H. Y. et al. Forkhead transcription factor FOXO3a is a negative regulator of angiogenic immediate early gene CYR61, leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ. Res. 100, 372–380 (2007). · DOI · Paper page
  125. Reynolds, A. R. et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nature Med. 15, 392–400 (2009). · DOI
  126. Hilfiker-Kleiner, D. et al. Regulation of proangiogenic factor CCN1 in cardiac muscle: impact of ischemia, pressure overload, and neurohumoral activation. Circulation 109, 2227–2233 (2004). · DOI · Paper page
  127. Dean, R. G. et al. Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J. Histochem. Cytochem. 53, 1245–1256 (2005). · DOI
  128. Panek, A. N. et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS ONE 4, e6743 (2009). · DOI
  129. Omoto, S. et al. Expression and localization of connective tissue growth factor (CTGF/Hcs24/CCN2) in osteoarthritic cartilage. Osteoarthr. Cartil. 12, 771–778 (2004). · DOI
  130. Blom, A. B. et al. Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt-induced signaling protein 1. Arthritis Rheum. 60, 501–512 (2009). · DOI
  131. Nishida, T. et al. Regeneration of defects in articular cartilage in rat knee joints by CCN2 (connective tissue growth factor). J. Bone Miner. Res. 19, 1308–1319 (2004). · DOI
  132. Nakata, E. et al. Expression of connective tissue growth factor/hypertrophic chondrocyte-specific gene product 24 (CTGF/Hcs24) during fracture healing. Bone 31, 441–447 (2002). · DOI · Paper page
  133. Nozawa, K. et al. Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis. Arthritis Res. Ther. 11, R174 (2009). · DOI
  134. Zhang, Q. et al. A critical role of Cyr61 in interleukin-17-dependent proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum. 60, 3602–3612 (2009). · DOI · Paper page
  135. Koon, H. W. et al. Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. Am. J. Pathol. 173, 400–410 (2008). · DOI · Paper page
  136. Ueberham, U., Ueberham, E., Gruschka, H. & Arendt, T. Connective tissue growth factor in Alzheimer's disease. Neuroscience 116, 1–6 (2003). · DOI · Paper page
  137. Zhao, Z. et al. Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance-associated promotion of Alzheimer's disease β-amyloid neuropathology. FASEB J. 19, 2081–2082 (2005). · DOI · Paper page
  138. Hurvitz, J. R. et al. Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia. Nature Genet. 23, 94–98 (1999). This report demonstrates that loss-of-function mutations in CCN6 are associated with progressive pseudorheumatoid dysplasia — a human autosomal recessive disorder. · DOI
  139. Nakamura, Y. et al. The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signaling. J. Clin. Invest. 117, 3075–3086 (2007). · DOI
  140. Fonseca, C. et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N. Engl. J. Med. 357, 1210–1220 (2007). · DOI
  141. Kawaguchi, Y. et al. Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population. Ann. Rheum. Dis. 68, 1921–1924 (2009). · DOI
  142. Granel, B. et al. Association between a CTGF gene polymorphism and systemic sclerosis in a French population. J. Rheumatol. 37, 351–358 (2010). · DOI
  143. Rueda, B. et al. A large multicentre analysis of CTGF-945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype. Ann. Rheum. Dis. 68, 1618–1620 (2009). · DOI
  144. Brigstock, D. R. Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): from pharmacological inhibition in vitro to targeted siRNA therapy in vivo. J. Cell Commun. Signal. 3, 5–18 (2009). This is a comprehensive summary of strategies targeting CCN2 in various animal models of organ fibrosis. · DOI
  145. Vial, C., Gutierrez, J., Santander, C., Cabrera, D. & Brandan, E. Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity. J. Biol. Chem. 286, 24242–24252 (2011). · DOI
  146. Desnoyers, L., Arnott, D. & Pennica, D. WISP-1 binds to decorin and biglycan. J. Biol. Chem. 276, 47599–47607 (2001). · DOI
  147. Wang, Q. et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair 4, 4 (2011). · DOI
  148. Mageto, Y., Flaherty, K., Brown, A. & Raghu, G. Safety and tolerability of human monoclonal antibody FG-3019, anti-connective tissue growth factor, in patients with idiopathic pulmonary fibrosis. Chest 126, 773S (2004). · DOI
  149. Zhang, Y. et al. MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. Am. J. Obstet. Gynecol. 202, 466–467 (2010). · DOI · Paper page
  150. Dendooven, A., Gerritsen, K. G., Nguyen, T. Q., Kok, R. J. & Goldschmeding, R. Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers 16, 289–301 (2011). · DOI
  151. D'Antonio, K. B. et al. Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment. Clin. Cancer Res. 16, 5908–5913 (2010). · DOI
  152. Katsube, K., Sakamoto, K., Tamamura, Y. & Yamaguchi, A. Role of CCN, a vertebrate specific gene family, in development. Dev. Growth Differ. 51, 55–67 (2009). · DOI
  153. Duisters, R. F. et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 104, 170–178 (2009). · DOI
  154. Ohgawara, T. et al. Regulation of chondrocytic phenotype by micro RNA 18a: involvement of Ccn2/Ctgf as a major target gene. FEBS Lett. 583, 1006–1010 (2009). · DOI
  155. Johannes, G., Carter, M. S., Eisen, M. B., Brown, P. O. & Sarnow, P. Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray. Proc. Natl Acad. Sci. USA 96, 13118–13123 (1999). · DOI · Paper page
  156. Mukudai, Y. et al. A coding RNA segment that enhances the ribosomal recruitment of chicken ccn1 mRNA. J. Cell Biochem. 111, 1607–1618 (2010). · DOI · Paper page
  157. Perbal, B. Alternative splicing of CCN mRNAs... it has been upon us. J. Cell Commun. Signal. 3, 153–157 (2009). · DOI
  158. Hirschfeld, M. et al. Expression of tumor-promoting Cyr61 is regulated by hTRA2-β1 and acidosis. Hum. Mol. Genet. 20, 2356–2365 (2011). · DOI
  159. Guillon-Munos, A. et al. Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors. J. Biol. Chem. 286, 25505–25518 (2011). · DOI
  160. Yang, W. et al. Impact of CCN3 (NOV) glycosylation on migration/invasion properties and cell growth of the choriocarcinoma cell line Jeg3. Hum. Reprod. 26, 2850–2860 (2011). · DOI
  161. Leng, E., Malcolm, T., Tai, G., Estable, M. & Sadowski, I. Organization and expression of the Cyr61 gene in normal human fibroblasts. J. Biomed. Sci. 9, 59–67 (2002).
  162. Sabbah, M. et al. CCN5, a novel transcriptional repressor of transforming growth factor-β signaling pathway. Mol. Cell Biol. 31, 1459–1469 (2011). · DOI · Paper page
  163. Hoshijima, M. et al. CT domain of CCN2/CTGF directly interacts with fibronectin and enhances cell adhesion of chondrocytes through integrin α5β1. FEBS Lett. 580, 1376–1382 (2006). · DOI
  164. Nishida, T. et al. CTGF/Hcs24, hypertrophic chondrocyte-specific gene product, interacts with perlecan in regulating the proliferation and differentiation of chondrocytes. J. Cell Physiol. 196, 265–275 (2003). · DOI
  165. Francischetti, I. M., Kotsyfakis, M., Andersen, J. F. & Lukszo, J. Cyr61/CCN1 displays high-affinity binding to the somatomedin B1–44 domain of vitronectin. PLoS ONE 5, e9356 (2010). · DOI
  166. Nishida, T. et al. Effect of CCN2 on FGF2-induced proliferation and MMP9 and MMP13 productions by chondrocytes. Endocrinology 152, 4232–4241 (2011). · DOI
  167. Gellhaus, A. et al. Connexin43 interacts with NOV: a possible mechanism for negative regulation of cell growth in choriocarcinoma cells. J. Biol. Chem. 279, 36931–36942 (2004). · DOI
  168. Fu, C. T., Bechberger, J. F., Ozog, M. A., Perbal, B. & Naus, C. C. CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. J. Biol. Chem. 279, 36943–36950 (2004). · DOI
  169. Kamata, H. et al. Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649–661 (2005). · DOI · Paper page
  170. Wu, S. H., Lu, C., Dong, L. & Chen, Z. Q. Signal transduction involved in CTGF-induced production of chemokines in mesangial cells. Growth Factors 26, 192–200 (2008). · DOI
  171. Canalis, E., Zanotti, S., Beamer, W. G., Economides, A. N. & Smerdel-Ramoya, A. Connective tissue growth factor is required for skeletal development and postnatal skeletal homeostasis in male mice. Endocrinology 151, 3490–3501 (2010). · DOI
  172. Doherty, H. E., Kim, H. S., Hiller, S., Sulik, K. K. & Maeda, N. A mouse strain where basal connective tissue growth factor gene expression can be switched from low to high. PLoS ONE 5, e12909 (2010). · DOI
  173. Tong, Z. et al. Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes. Hepatology 50, 939–947 (2009). · DOI
  174. Watari, H., Xiong, Y., Hassan, M. K. & Sakuragi, N. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol. Oncol. 112, 229–234 (2009). · DOI
  175. Chien, W. et al. Cyr61 suppresses growth of human endometrial cancer cells. J. Biol. Chem. 279, 53087–53096 (2004). · DOI
  176. Kikuchi, R. et al. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res. 67, 7095–7105 (2007). · DOI · Paper page
  177. Tong, X. et al. Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J. Biol. Chem. 276, 47709–47714 (2001). · DOI · Paper page
  178. Dhar, G. et al. Loss of WISP-2/CCN5 signaling in human pancreatic cancer: a potential mechanism for epithelial-mesenchymal-transition. Cancer Lett. 254, 63–70 (2007). · DOI
  179. Ladwa, R., Pringle, H., Kumar, R. & West, K. Expression of CTGF and Cyr61 in colorectal cancer. J. Clin. Pathol. 64, 58–64 (2011). · DOI
  180. Croci, S. et al. Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res. 64, 1730–1736 (2004). · DOI
  181. Boag, J. M. et al. High expression of connective tissue growth factor in pre-B acute lymphoblastic leukaemia. Br. J. Haematol. 138, 740–748 (2007). · DOI
  182. Bouchard, L. et al. CYR61 polymorphisms are associated with plasma HDL-cholesterol levels in obese individuals. Clin. Genet. 72, 224–229 (2007). · DOI
  183. Fernandez-Rozadilla, C. et al. Colorectal cancer susceptibility quantitative trait loci in mice as a novel approach to detect low-penetrance variants in humans: a two-stage case-control study. Cancer Epidemiol. Biomarkers Prev. 19, 619–623 (2010). · DOI
  184. Dessein, A. et al. Variants of CTGF are associated with hepatic fibrosis in Chinese, Sudanese, and Brazilians infected with schistosomes. J. Exp. Med. 206, 2321–2328 (2009). · DOI
  185. Cozzolino, M. et al. CCN2 (CTGF) gene polymorphism is a novel prognostic risk factor for cardiovascular outcomes in hemodialysis patients. Blood Purif. 30, 272–276 (2010). · DOI
  186. Ortlepp, J. R. et al. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur. Heart J. 25, 514–522 (2004). · DOI
  187. Wang, B. et al. Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. J. Med. Genet. 47, 391–397 (2010). · DOI
  188. Yamada, Y., Ando, F. & Shimokata, H. Association of polymorphisms of SORBS1, GCK and WISP1 with hypertension in community-dwelling Japanese individuals. Hypertens. Res. 32, 325–331 (2009). · DOI
  189. Urano, T. et al. Association of a single nucleotide polymorphism in the WISP1 gene with spinal osteoarthritis in postmenopausal Japanese women. J. Bone Miner. Metab. 25, 253–258 (2007). · DOI
  190. Thorstensen, L. et al. WNT1 inducible signaling pathway protein 3, WISP-3, a novel target gene in colorectal carcinomas with microsatellite instability. Gastroenterology 121, 1275–1280 (2001). · DOI
  191. Lamb, R., Thomson, W., Ogilvie, E. & Donn, R. Wnt-1-inducible signaling pathway protein 3 and susceptibility to juvenile idiopathic arthritis. Arthritis Rheum. 52, 3548–3553 (2005). · DOI

Cited by

Sorted by citations

Metadata

Authors
Jun, J.-I., & Lau, L. F.
Venue
Nature Reviews Drug Discovery
Publisher
Springer Science and Business Media LLC
Published
2011-12
Volume
10
Issue
12
Pages
945-963
ISSN
  • 1474-1776
  • 1474-1784
DOI
10.1038/nrd3599
PMC
PMC3663145
Cited by
568
References
29
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review